During the last decades, diverse non-invasive blood testing has been developed, plasma biomarkers (e.g. high-density lipoprotein cholesterol (HDL-C), biglycan (BGN), cytokeratin 18 (CK18), pro collagen III (Pro-C3) and plasma N-terminal propeptide of type III procollagen (PIIINP)) are commonly used to reflect specific and complex molecular mechanisms underlying the pathogenesis and progression of NAFLD and NASH (154, 223). This evidence concerns the gene KRT18 and metabolic dysfunction-associated steatohepatitis.